Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105


Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany.

Pfohl M, Schädlich PK, Dippel FW, Koltermann KC.

J Med Econ. 2012;15 Suppl 2:14-27. doi: 10.3111/13696998.2012.713879. Epub 2012 Aug 3.


[Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].

Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.

Dtsch Med Wochenschr. 2009 Jun;134(23):1207-13. doi: 10.1055/s-0029-1222595. Epub 2009 May 26. German. Erratum in: Dtsch Med Wochenschr. 2009 Jun;134(24):1256.


Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.

Schöffski O, Breitscheidel L, Benter U, Dippel FW, Müller M, Volk M, Pfohl M.

J Med Econ. 2008;11(4):695-712. doi: 10.3111/13696990802645726.


Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis.

Pscherer S, Chou E, Dippel FW, Rathmann W, Kostev K.

Prim Care Diabetes. 2015 Oct;9(5):377-84. doi: 10.1016/j.pcd.2015.01.011. Epub 2015 Feb 18.


Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in Type-2 diabetic patients: comparison of insulin glargine with NPH insulin.

Quinzler R, Ude M, Franzmann A, Feldt S, Schüssel K, Leuner K, Müller WE, Dippel FW, Schulz M.

Int J Clin Pharmacol Ther. 2012 Jan;50(1):24-32.


Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.


Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.

Haukka J, Hoti F, Erästö P, Saukkonen T, Mäkimattila S, Korhonen P.

Pharmacoepidemiol Drug Saf. 2013 Dec;22(12):1326-35. doi: 10.1002/pds.3534. Epub 2013 Oct 21.


A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK.

Idris I, Gordon J, Tilling C, Vora J.

J Med Econ. 2015 Apr;18(4):273-82. doi: 10.3111/13696998.2014.991788. Epub 2014 Dec 4.


Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database.

Laubner K, Molz K, Kerner W, Karges W, Lang W, Dapp A, Schütt M, Best F, Seufert J, Holl RW.

Diabetes Metab Res Rev. 2014 Jul;30(5):395-404. doi: 10.1002/dmrr.2500.


Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review.

Caires de Souza AL, de Assis Acurcio F, Guerra Júnior AA, Rezende Macedo do Nascimento RC, Godman B, Diniz LM.

Appl Health Econ Health Policy. 2014 Feb;12(1):19-32. doi: 10.1007/s40258-013-0073-6. Review.


Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.

Home PD, Bolli GB, Mathieu C, Deerochanawong C, Landgraf W, Candelas C, Pilorget V, Dain MP, Riddle MC.

Diabetes Obes Metab. 2015 Jan;17(1):15-22. doi: 10.1111/dom.12329. Epub 2014 Jul 12.


Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis.

Lee P, Chang A, Blaum C, Vlajnic A, Gao L, Halter J.

J Am Geriatr Soc. 2012 Jan;60(1):51-9. doi: 10.1111/j.1532-5415.2011.03773.x.


Institution of basal-bolus therapy at diagnosis for children with type 1 diabetes mellitus.

Adhikari S, Adams-Huet B, Wang YC, Marks JF, White PC.

Pediatrics. 2009 Apr;123(4):e673-8. doi: 10.1542/peds.2008-3027. Epub 2009 Mar 2.


Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.

Rosenstock J, Fonseca V, Schinzel S, Dain MP, Mullins P, Riddle M.

J Diabetes Complications. 2014 Sep-Oct;28(5):742-9. doi: 10.1016/j.jdiacomp.2014.04.003. Epub 2014 Apr 16.


Risk of diabetic foot ulceration during treatment with insulin glargine and NPH insulin.

Kostev K, Dippel FW, Rockel T, Siegmund T.

J Wound Care. 2012 Oct;21(10):483-4, 486-9.


Supplemental Content

Support Center